We are Renalytix.
Our singular goal is to
eradicate kidney disease.
Kidney disease affects more people than cancer and heart disease combined.
850 million people worldwide suffer with chronic kidney disease (CKD). And it is believed that CKD will become the 5th leading cause of death in the world by 2040.
To turn the corner, we must shift the focus from kidney disease to kidney health.
Only then can we chart a new and, more clinically- and cost-effective path forward.
Another medical innovation.
Incredibly, scientists have learned how to edit genes to decrease chronic illness. They’ve invented medications to prevent the spread of deadly diseases, like HIV. They even discovered multiple COVID-19 vaccines in less than one year. And now, we are proud to join that list of important medical innovations.
Recognized by the FDA with Breakthrough Designation
KidneyIntelX is a highly-reliable, bioprognostic™ methodology, that yields a simple-to-understand, custom risk score, predicting which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3b are at low, intermediate or high risk for rapid progressive decline in kidney function.
When doctors combine information gathered through KidneyIntelX with newer cardio- and reno-protective therapies, they know which patients are at higher to lower risk for rapid disease progression, and therefore, can appropriately target resources and guideline-recommended treatments to advance kidney health.
Join our growing roster
of world-class partners.
Let’s stand together to change the lives of so many.
University of Michigan
University of Utah
National Kidney Foundation
And in these prominent publications.
Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.